Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 3:16 pm Sale | 2020-12-31 | 13G | Cytokinetics, Incorporated CYTK | Point72 Asset Management, L.P. | 1,176,653 1.700% | -1,855,196 (-61.19%) | Filing History |
| 2021-02-16 3:16 pm Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Point72 Asset Management, L.P. | 3,691,632 2.100% | -4,696,422 (-55.99%) | Filing History |
| 2021-02-16 3:15 pm Purchase | 2020-12-31 | 13G | BELLUS Health Inc. BLU | Point72 Asset Management, L.P. | 6,240,116 8.000% | 20,058 (+0.32%) | Filing History |
| 2021-02-16 3:14 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Point72 Asset Management, L.P. | 117,191 6.100% | 1,672 (+1.45%) | Filing History |
| 2021-02-16 3:13 pm Sale | 2020-12-31 | 13G | Aptevo Therapeutics Inc. APVO | Point72 Asset Management, L.P. | 0 0.000% | -0 (Position Closed) | Filing History |
| 2021-02-16 3:13 pm Sale | 2020-12-31 | 13G | Bread Financial Holdings, Inc. BFH | Point72 Asset Management, L.P. | 1,125,848 1.800% | -1,903,565 (-62.84%) | Filing History |
| 2021-02-16 3:12 pm Sale | 2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Point72 Asset Management, L.P. | 3,969 0.100% | -227,548 (-98.29%) | Filing History |
| 2021-02-16 3:11 pm Sale | 2020-12-31 | 13G | SunOpta Inc. STKL | Point72 Asset Management, L.P. | 62,298 0.100% | -5,461,179 (-98.87%) | Filing History |
| 2021-02-16 3:10 pm Purchase | 2020-12-31 | 13G | Acorda Therapeutics, Inc. ACOR | Point72 Asset Management, L.P. | 45,168 1.900% | 5,985 (+15.28%) | Filing History |
| 2021-02-16 3:09 pm Purchase | 2020-12-31 | 13G | OAKTREE ACQUISITION CORP OAC | Point72 Asset Management, L.P. | 1,300,100 6.500% | 185,000 (+16.59%) | Filing History |
| 2021-02-16 3:09 pm Purchase | 2020-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Point72 Asset Management, L.P. | 426,162 10.900% | 426,162 (New Position) | Filing History |
| 2021-02-08 5:21 pm Purchase | 2021-01-27 | 13G | Affimed N.V. AFMD | Point72 Asset Management, L.P. | 581,461 5.000% | 581,461 (New Position) | Filing History |
| 2021-01-27 5:19 pm Purchase | 2021-01-26 | 13G | ALTIMAR ACQUISITION CORP ATAC | Point72 Asset Management, L.P. | 1,400,000 5.100% | 1,400,000 (New Position) | Filing History |
| 2021-01-26 5:20 pm Purchase | 2021-01-25 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 5,523,906 9.100% | 5,523,906 (New Position) | Filing History |